Directorate Change

RNS Number : 4314D
Edinburgh Worldwide Inv Trust PLC
19 October 2022
 

Edinburgh Worldwide Investment Trust plc ('EWI')

 

Legal Entity Identifier: 213800JUA8RKIDDLH380

 

Appointment of New Directors and Retiral of Mr Donald Cameron

 

The Board is pleased to announce the appointment of Ms Jane McCracken as a non-executive Director of the Company with effect from 1 November 2022 and Dr Mary Gunn as a non-executive Director of the Company with effect from 1 March 2023.

 

Ms Jane McCracken has spent her career working with high growth technology businesses based in the USA and UK as an entrepreneur, equity investor, board member and advisor. Her experience covers a variety of areas including enterprise software, e-commerce, fintech, digital health and clinical research. Most recently, she served as a Research Faculty member and Entrepreneur-in-Residence at the Georgia Institute of Technology in Atlanta, Georgia, USA and currently is the Chief Growth Officer for Corps Team LLC. She is also a non-executive director of Radyus Research LLC.

 

Dr Mary Gunn is a scientist, lawyer and C-level executive in life science companies, including previously at Pfizer, Crucell, ICON Plc and Health Decisions. She also served on the boards and advisories of Brown University, Modelis, Lumiio and SpotArt Foundation. She is currently an Independent Director of Welwaze Medical and the President of RemRem LLC, a value creation advisory for investors, banks and entrepreneurs in clinical research and life science.

 

The appointment of Ms McCracken and Dr Gunn fall to be ratified by shareholders at the Annual General Meeting of the Company to be held in March 2023.

 

As commented on in the 31 October 2021 Annual Report and Financial Statements Mr Donald Cameron will not be standing for re-election at the Annual General Meeting to be held in March 2023.

 

There is no further information required to be disclosed under Listing Rule 9.6.13.

 

 

Baillie Gifford & Co Limited

Managers and Secretaries

19 October 2022

 

Regulated Information Classification: Additional regulatory information required to be disclosed under applicable laws and regulations.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOADZMMGGLMGZZM
Investor Meets Company
UK 100